FDA Approves Cemiplimab-rwlc for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma By Ogkologos - October 27, 2025 245 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the C-POST study Source RELATED ARTICLESMORE FROM AUTHOR EMA Adopts a Positive Opinion for a New Route of Administration Together with a New Pharmaceutical Form and a New Strength for Isatuximab National Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients with Advanced ROS1-positive NSCLC MOST POPULAR New Research Looks for More Effective Breast Cancer Treatments for Black... January 12, 2021 FDA Approves Entrectinib Based on Tumor Genetics Rather Than Cancer Type September 17, 2019 Vaping Pods Produce High Nicotine Levels in Young Users October 5, 2018 ¿Qué es la escasez de medicamentos y cómo puede afectar a... June 30, 2023 Load more HOT NEWS EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel Mobile Care Center Brings Breast Cancer Treatment to Amish and Mennonite... Your questions on our research strategy News digest – targeted ‘lava lamp’ treatment, skin cancer biopsies and...
